Tympanogen
1 known investors
Tympanogen develops Perf-Fix, a gel patch system for nonsurgical eardrum (tympanic membrane) repair that replaces traditional tympanoplasty with a clinic-based procedure. The product is aimed at ENT surgeons and clinicians for outpatient otologic care and is currently in development.
BiotechHealthtechMedical Devices
Investors · 1
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $3.2M |
| Department of DefenseDefense Health Program | Phase I | 2020 | $250K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $1.5M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Tympanogen do?
- Tympanogen develops Perf-Fix, a gel patch system for nonsurgical eardrum (tympanic membrane) repair that replaces traditional tympanoplasty with a clinic-based procedure. The product is aimed at ENT surgeons and clinicians for outpatient otologic care and is currently in development.
- Who are Tympanogen's investors?
- Tympanogen's investors include Citrine Angels.